Related Experiment Video
Updated: May 24, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use
Vivek Iyer1, Harsimran S Singh, James A Reiffel
1Department of Medicine, Division of Cardiology, Columbia University Medical Center, NY 10032, USA.
Journal of Cardiovascular Pharmacology and Therapeutics
|March 6, 2012
Summary
New oral anticoagulants like dabigatran etexilate offer superior stroke risk reduction for atrial fibrillation (AF) patients compared to warfarin. This review discusses dabigatran
Area of Science:
- Cardiology
- Pharmacology
- Neurology
Background:
- Atrial fibrillation (AF) impacts millions, increasing stroke risk.
- Current anticoagulants (warfarin) have limitations.
- New oral anticoagulants (NOACs) offer alternatives.
Purpose of the Study:
- To review stroke prevention options in the NOAC era.
- To summarize warfarin's efficacy and obstacles.
- To discuss dabigatran's role in managing AF stroke risk.
Main Methods:
- Review of existing literature on anticoagulation for AF.
- Analysis of dabigatran etexilate's mechanism, efficacy, and safety.
- Discussion of practical considerations for dabigatran use.
Main Results:
- Dabigatran etexilate shows superior stroke risk reduction versus warfarin.
- Dabigatran etexilate is the first new FDA-approved agent for AF stroke prevention in over 50 years.
- The review covers pharmacokinetics, initiation, and special populations.
Conclusions:
- Dabigatran etexilate represents a significant advancement in AF stroke prevention.
- Understanding NOACs, like dabigatran, is crucial for clinicians.
- Dabigatran offers a valuable option for managing stroke risk in AF patients.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...